(Motley Fool) Inovio Pharmaceuticals Inc. (NASDAQ:INO) announced that Dr. J. Joseph Kim, President and CEO, will present at Rodman & Renshaws 17th Annual Global Investment Conference and participate in one-on-one meetings at Citis 10th Annual Biotech Conference. Both events will be held in New York, NY from September 9-10.
Inovio Pharmaceuticals Equity Analysis
Inovio Pharmaceuticals Inc. (NASDAQ:INO) opened trading today as $7.73 and is trading in the range of 7.30-7.74 today. Inovio Pharmaceuticals’ current market cap stands at $557.46 million.
Compared to other peers in the Biotechnology sector, Inovio Pharmaceuticals has outperformed in terms of quarterly revenue growth year over year at .39 vs. the industry average of 0.19. Inovio Pharmaceuticals’ earnings per share is currently at -0.53, which is below then the sector average of -0.33.
Inovio Pharmaceuticals is currently covered by 5 Wall Street analysts. The mean target price is $21.40 according to First Call. This presents a solid upside to the current price of the equity. The Mean Recommendation sits at 1.6 which is based on, 2 strong buy and 3 Buy.
The most recent analyst actions consisted of H.C. Wainwright initiating the stock on March 12th and Aegis Capital initiating coverage with an upgrading rating back in July.
The current quarter EPS consensus estimate is -0.04 with revenue estimates of 14.60M Sales are expected to grow at a 693.50% rate. Inovio Pharmaceuticals reported actual earnings last quarter of -0.09 which beat the -0.13 consensus estimate, a 30.80% surprise.
Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The companys DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The companys clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.